
Enfuvirtide (T-20) Peptide

Subcategory: Synthetic Peptide

Cat. No.: 350164

Unit: 1 mg

Description:

Enfuvirtide is an envelope fusion inhibitor used to treat HIV-infected patients. The peptide binds to the HIV envelope glycoprotein gp41 and prevents viral fusion with the target cell membrane. Enfuvirtide (Fuzeon/Roche) was approved by the FDA in 2003.

Format: Each vial contains 1 mg of lyophilized solid packaged under an inert gas and supplied as a trifluoroacetate salt.

Alternate Names: Enfuvirtide; Fuzeon; envelope glycoprotein gp160; glycoprotein 120

Accession No.: P03375

MW: 4492 g/mol

Sequence: Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH₂ or H-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH₂

Composition: C₂₀₄H₃₀₁N₅₁O₆₄

Purity: Purity > 95% by HPLC

Solubility: Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.

Storage: Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, aliquot and store at -20°C.

For research use only, not for diagnostic or therapeutic procedures.